VMS BioMarketing, a company dedicated to helping patients successfully start and stay on therapies, has appointed Kristin Sherman chief financial
officer. She previously served as CFO at Calibrium LLC. Sherman provided finance, legal and human resources oversight including coordination of the company’s initial financing, management of strategic partnerships with universities and pharmaceutical companies, and oversight of the final sale of the company to Novo Nordisk. Immediately prior to Calibrium, Sherman held similar roles for two additional biotech start-ups including MarcadiaBiotech until its acquisition by Roche in 2010 and AgeneBio, which focused on Alzheimer’s disease. In addition, Sherman served as the treasurer and vice president of finance for Guidant Corp. during the sale of Guidantto Abbott and Boston Scientific. She also held a variety of management positions including serving as Guidant’s first finance director for emerging markets. Sherman began her career in various finance positions with Eli Lilly and Company and was assistant treasurer during Guidant’s spin-off from Lilly.  In her new role, she will oversee finance, data and analytics, and human resources.

{{ articles_remaining }}
Free {{ article_text }} Remaining
{{ articles_remaining }}
Free {{ article_text }} Remaining Article limit resets on
{{ count_down }}